Cycloserine

Specifications

68-41-7CAS Number

200-688-4EC Number

(4R)-4-amino-1,2-oxazolidin-3-oneIUPAC Name

C3H6N2O2Chemical Formula

102.09 g/molMolecular Weight

D-cycloserine; cycloserine; 68-41-7; Seromycin; orientomycin; Oxamycin; Cyclo-D-serine; Cicloserina; Cyclorin; Farmiserina; Tisomycin; Wasserina; Miroseryn; Closina; D-4-amino-3-isoxazolidinone; (4R)-4-amino-1,2-oxazolidin-3-one; Cycloserinum; Novoserin; (+)-4-Amino-3-isoxazolidinone; alpha-Cycloserine; D-4-amino-3-isoxazolidone; (+)-Cycloserine; (4R)-4-aminoisoxazolidin-3-one; PA 94; PA-94; D-(+)-Cycloserine; RO-1-9213; 3-Isoxazolidinone, 4-amino-, (R)-; 3-Isoxazolidinone, 4-amino-, d-; 3-Isoxazolidinone, 4-amino-, (+)-; DTXSID8022870; 95IK5KI84Z; CHEBI:40009; NSC-76029; NSC-154851; DTXCID902870; NSC154851; R-4-Amino-3-isoxazolidinone; RefChem:56415; J04AB01; (4R)-4-azaniumyl-4,5-dihydro-1,2-oxazol-3-olate; 200-688-4; (R)-4-AMINOISOXAZOLIDIN-3-ONE; Miroserina; Tebemicina; Oxamicina; 3-Isoxazolidinone, 4-amino-, (4R)-; Cycloserin; Micoserina; E-733-A; (R)-4-AMINO-ISOXAZOLIDIN-3-ONE; D-Oxamycin; D-CS; D-4-Amino-3-isossazolidone; MFCD00005353; K-300; (R)-4-Amino-3-isoxazolidone; I-1431; HSDB 3218; D-Oxamicina; D-Cycloserine (Standard); NSC 154851; AI3-50153; C3H6N2O2; D-Cycloserine, synthetic; DCS; CHEMBL771; SC-49088; CAS-68-41-7; NCGC00016306-01; Oxamicina [Italian]; Cicloserina [Italian]; M01471; Cycloserinum [INN-Latin]; Cicloserina [INN-Spanish]; Cycloserine, D-; Orientmycin; Closerin; (R)-(+)-Cycloserine; .alpha.-Cycloserine; (R)-Cycloserine; Seromycin (TN); 4AX; SMR000058313; D-4-Amino-3-isossazolidone [Italian]; R-(+)-Cycloserine; (R)-4-Amino-3-isoxazolidinone; (4R)-4-Amino-3-isoxazolidinone; CYCLOSERINE (D); SR-01000075432; DRG-0195; EINECS 200-688-4; D-amino-3-isoxazolidinone; BRN 0080798; UNII-95IK5KI84Z; Orientomycin;; Cyclomycin;; Farmiserina;; Micoserina;; Seromycin;; Cycloserine RS; Oxamycin;; Oxymycin;; Closina;; cycloserine-(d); Serine, cyclo-; 3-Isoxazolidinone, 4-amino-, D; R(+)-4-Amino-3-isoxazolidinone; Cycloserine [USP:INN:BAN:JAN]; NJ-21; 3-Isoxazolidinone, 4-amino-, (R); (R)-(+)-4-Amino-3-isoxazolidinone; Antibiotic 5915;; Antibiotic 8217;; Cycloserine, D(+); Antibiotic NJ 21;; Antibiotic PA 94;; D-Cycloserine, powder; Antibiotic K 300;; Spectrum_000860; 1pb9; Antibiotic 106-7;; Antibiotic 17452;; Antibiotic E 733A;; Antibiotic I 1431;; CYCLOSERINE [MI]; Prestwick0_001089; Prestwick1_001089; Prestwick2_001089; Prestwick3_001089; Spectrum2_000084; Spectrum3_000371; Spectrum4_000305; Spectrum5_000797; CYCLOSERINE [INN]; CYCLOSERINE [JAN]; Lopac-C-1159; Lopac-C-3909; Lopac-C-7005; CYCLOSERINE [HSDB]; 3-Isoxazolidinone, 4-amino-, (4R)- (9CI); C 3909; CYCLOSERINE [VANDF]; Antibiotic Ro 1-9213;; CYCLOSERINE [MART.]; Lopac0_000252; SCHEMBL34322; BSPBio_001138; BSPBio_002121; CYCLOSERINE [WHO-DD]; CYCLOSERINE [WHO-IP]; KBioGR_000890; KBioSS_001340; 4-27-00-05549 (Beilstein Handbook Reference); MLS000758215; MLS001423962; MLS002548887; BIDD:GT0707; D-Cycloserine synth. BP 88; DivK1c_000098; SPECTRUM1500215; SPBio_000008; SPBio_003029; BPBio1_001252; FA6C7F8B-D080-4EA3-978F-1ECFB5A29D09; GTPL9489; orb1224251; orb1308085; orb3141370; Cycloserine (JP18/USP/INN); 4-Amino-3-isoxazolidinone, D-; HMS500E20; HY-B0030R; KBio1_000098; KBio2_001340; KBio2_003908; KBio2_006476; KBio3_001341; CYCLOSERINE [ORANGE BOOK]; NINDS_000098; CYCLOSERINE [USP IMPURITY]; HMS1571I20; HMS1920C06; HMS2051C15; HMS2091I14; HMS2098I20; HMS2232F03; HMS3259L19; HMS3260D06; HMS3715I14; Pharmakon1600-01500215; CYCLOSERINE [USP MONOGRAPH]; (R)-3-Isoxazolidinone, 4-amino-; 4-Amino-3-isoxazolidinone, (R)-; CYCLOSERINUM [WHO-IP LATIN]; HY-B0030; Tox21_110361; Tox21_500252; BDBM50038178; BDBM50103516; CCG-39705; D-Cycloserine, >=96.0% (NT); EBC-03937; LMPK14000007; NSC756712; 4-Isoxazolidinamine, 3-oxo-, (D)-; AKOS015994626; Tox21_110361_1; AC-4721; D-Cycloserine, Streptomyces orchidaceus; DB00260; FC15208; HS-0079; LP00252; NC00050; NC00676; NSC-756712; SDCCGSBI-0050240.P005; IDI1_000098; SMP1_000167; NCGC00015213-01; NCGC00015213-02; NCGC00015213-03; NCGC00016306-02; NCGC00016306-03; NCGC00016306-04; NCGC00016306-05; NCGC00016306-07; NCGC00016306-08; NCGC00016306-13; NCGC00016306-17; NCGC00093713-01; NCGC00093713-02; NCGC00260937-01; CAS-339-72-0; ST075697; SY005636; SBI-0050240.P004; AB00443920; C9610; CS-0695020; EU-0100252; NS00009120; 3-Isoxazolidinone, 4-amino-, (+)- (8CI); EN300-97131; (4R)-4-amino-2,4,5-trihydroisoxazol-3-one; C08057; D00877; AB00443920_09; AB00443920_10; Q418508; SR-01000759389; SR-01000075432-1; SR-01000075432-2; SR-01000075432-5; SR-01000075432-9; SR-01000759389-4; BRD-K87226815-001-17-1; BRD-K87226815-001-18-9; BRD-K87226815-001-19-7; BRD-K87226815-001-20-5; SR-01000075432-10; F2173-1228; Z1198154206; Cycloserine, United States Pharmacopeia (USP) Reference Standard; Cycloserine, Pharmaceutical Secondary Standard; Certified Reference MaterialSynonyms